Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EPS (Basic) (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed EPS (Basic) for 14 consecutive years, with -$0.42 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 60.0% year-over-year to -$0.42, compared with a TTM value of -$3.21 through Dec 2025, up 35.15%, and an annual FY2025 reading of -$3.84, up 29.93% over the prior year.
  • EPS (Basic) was -$0.42 for Q4 2025 at Enanta Pharmaceuticals, up from -$0.88 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.42 in Q4 2025 and bottomed at -$1.86 in Q2 2023.
  • Average EPS (Basic) over 5 years is -$1.28, with a median of -$1.3 recorded in 2022.
  • The sharpest move saw EPS (Basic) plummeted 263.33% in 2021, then soared 60.0% in 2025.
  • Year by year, EPS (Basic) stood at -$1.48 in 2021, then increased by 6.08% to -$1.39 in 2022, then fell by 13.67% to -$1.58 in 2023, then skyrocketed by 33.54% to -$1.05 in 2024, then skyrocketed by 60.0% to -$0.42 in 2025.
  • Business Quant data shows EPS (Basic) for ENTA at -$0.42 in Q4 2025, -$0.88 in Q3 2025, and -$0.85 in Q2 2025.